[July 27, 2016]

Senseonics Holdings, Inc. to present at Canaccord Genuity's Growth Conference

Senseonics Holdings, Inc. (NYSE-MKT:SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the company plans to participate in Canaccord Genuity's Growth Conference in Boston, Massachusetts.

Senseonics' management is scheduled to present Wednesday, August 10, 2016 at 10:00 a.m. EDT. Interested parties can access the live audio webcast by navigating to the "Events & Publications" section of the "Investor Relations" tab at www.senseonics.com. An archived presentation wil also be available on the website.

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics' first generation continuous glucose monitoring system, Eversense®, includes a small sensor, smart transmitter and mobile application. Based on fluorescence sensing technology, the sensor is designed to be inserted subcutaneously and communicate with the smart transmitter to wirelessly transmit glucose levels to a mobile device. After insertion, the sensor is designed to continually and accurately measure glucose levels. For more information on Senseonics, please visit www.senseonics.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160727006587/en/

[ Back To Mobile World Congress's Homepage ]